Catalfamo Luciano, De Ponte Francesco Saverio, De Rinaldis Danilo
Department of Biomedical, Dental and Morphological and Functional Imaging (BIOMORF), University of Messina, Via Consolare Valeria 1, 98124 Messina, Italy.
J Clin Med. 2025 Jul 25;14(15):5269. doi: 10.3390/jcm14155269.
"Ozempic face" is an aesthetic side effect associated with the use of the antidiabetic agent Ozempic (semaglutide), characterized by a prematurely aged and fatigued facial appearance due to rapid weight loss. Currently, treatment options for this condition are limited. In this study, we present our clinical experience with the device, provided by (Rome, Italy). We report a case series involving 24 patients (19 women and 5 men, aged 27-65 years), treated with subdermal bipolar radiofrequency (Endotissutal Bipolar Radiofrequency) between 2023 and 2024. All patients underwent a minimum follow-up of 12 months. At the end of the follow-up period, patients rated their satisfaction on a from 0 to 10 scale, and an independent expert assessed the stability of clinical outcomes. The majority of patients reported high satisfaction levels (≥8), which correlated with the independent expert's evaluation of treatment efficacy and result stability. The only observed adverse event was transient cutaneous erythema. "Ozempic face" is an increasingly common side effect associated with newer classes of antidiabetic medications. Although these drugs offer significant metabolic benefits, the accompanying facial volume loss and aging are often poorly tolerated by patients. Our findings suggest that subdermal bipolar radiofrequency represents a safe, low-risk, and cost-effective therapeutic option for the aesthetic management of Ozempic face.
“司美格鲁肽面容”是一种与使用抗糖尿病药物司美格鲁肽（Ozempic，即索马鲁肽）相关的美学副作用，其特征是由于体重快速减轻导致面部过早衰老和疲惫。目前，针对这种情况的治疗选择有限。在本研究中，我们介绍了由（意大利罗马）提供的该设备的临床经验。我们报告了一个病例系列，涉及24名患者（19名女性和5名男性，年龄在27至65岁之间），于2023年至2024年期间接受了皮下双极射频治疗（Endotissutal Bipolar Radiofrequency）。所有患者均接受了至少12个月的随访。在随访期结束时，患者以0至10分的量表对满意度进行评分，并且由一名独立专家评估临床结果的稳定性。大多数患者报告了较高的满意度（≥8分），这与独立专家对治疗效果和结果稳定性的评估相关。唯一观察到的不良事件是短暂的皮肤红斑。“司美格鲁肽面容”是一种与新型抗糖尿病药物相关的日益常见的副作用。尽管这些药物具有显著的代谢益处，但随之而来的面部容积减少和衰老往往患者难以耐受。我们的研究结果表明，皮下双极射频是一种用于司美格鲁肽面容美学管理的安全、低风险且具有成本效益的治疗选择。
